Australia's largest stock trading and investment forum Australia's #1 stock forum

PER

2.50%

8.2¢ percheron therapeutics limited

Ann: Company Update, page-16

First 16 Last

Share
Profile

Follow
itsagas

13,236 Posts.

1403

09/12/14

13:06

Post #: 14432433
Share

Originally posted by peaceAKKI ↑

That's the problem though for a drug without approval and only 8 week phase II trial in 70 patients that still hasn't shown the measures MS drugs have been approved on who will cover the costs ?

In respect of being unapproved it then remains an experimental treatment right ?

I think you will struggle to find any government let alone insurance companies willing to cover costs but again happy to be proven wrong.

An approved drug though and one under PBS (or the like) sure it covers the lion share that's why being granted PBS is such a big deal for companies there market increases many multiples. In Australia use Copaxone & Tysabri for example as they are roughly the same costs say $30K pa but after PBS it comes down for the patient to between $70 & $400 each year.

On a plus side I guess they say they are focussing on Europe and I think in Europe far less drugs are covered by the government so probably takes a lot of the cheap options for patients out of the picture.

Expand

Peace the FDA are happy for atl 1102 to go into Phase 2 b.
The American Neuro Academy were more than happy with the TOX studies ...
Anp management have done DD on the sale of MS drugs in EUROPE..

Everyone is happy except you Peace..

Hmmmm who do we believe ?...

ANP Price at posting: 9.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

As Nvidia cools, we're looking to Aussie AI

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

There are more pages in this discussion • 95 more messages in this thread...

First 16 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.2¢		Change 0.002(2.50%)		Mkt cap ! $73.92M

Open	High	Low	Value	Volume
8.0¢	8.2¢	7.9¢	$16.80K	210.0K

Buyers (Bids)

No.	Vol.	Price($)
1	24999	7.9¢

Sellers (Offers)

Price($)	Vol.	No.
8.3¢	31992	1

View Market Depth

No.	Vol.	Price($)
1	24999	0.079
2	60000	0.078
2	114144	0.077
2	46800	0.075
1	100000	0.074

Price($)	Vol.	No.
0.083	31992	1
0.084	100000	1
0.085	136669	3
0.086	33375	2
0.087	531562	3

Last trade - 16.10pm 06/09/2024 (20 minute delay)

PER (ASX) Chart

Ann: Company Update, page-16

As Nvidia cools, we're looking to Aussie AI

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Company Update, page-16

Top Stories

As Nvidia cools, we're looking to Aussie AI

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News